Lysogene
Lysogene is a clinical stage pioneering biotechnology company in the field of gene therapy targeting severe genetic pathologies of central nervous system in children. The company went public in 2017 on the Euronext Stock Exchange (FR0013233475 / LYS)
Sector
Biopharmaceuticals
Strategies
Status
Live
Website
www.lysogene.com
Related News
Lysogene announces its successful IPO on Euronext Paris with nearly €22.6 m raised
Lysogene Receives Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA
Lysogene appoints Annette Clancy as Chair of the Board
Lysogène, University of Massachusetts Medical School and Auburn Unniversity announce collaboration agreement
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.